Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population.
Adolescent
Adult
Alcohol Drinking
/ epidemiology
Alcoholism
/ epidemiology
Anxiety Disorders
/ epidemiology
Depressive Disorder
/ epidemiology
Diagnostic and Statistical Manual of Mental Disorders
Female
Follow-Up Studies
Humans
Male
Middle Aged
Odds Ratio
Risk Assessment
/ standards
United States
/ epidemiology
World Health Organization
Young Adult
Alcohol
Alcohol use disorder
Anxiety
Depression
Drinking reduction
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
31
08
2018
revised:
28
12
2018
accepted:
03
01
2019
pubmed:
11
3
2019
medline:
27
6
2019
entrez:
11
3
2019
Statut:
ppublish
Résumé
Non-abstinent drinking reductions that predict improvement in how individuals feel or function, such as the World Health Organization (WHO) drinking risk levels, may be useful outcomes in clinical trials for alcohol use disorders (AUD). Current drinkers in a U.S. national survey (n = 22,005) were interviewed in 2001-02 (Wave 1) and re-interviewed 3 years later (Wave 2). WHO drinking risk levels, a 4- level categorization system (very-high-risk, high-risk, moderate-risk, and low-risk drinkers) defined using estimated mean ethanol consumption (grams) per day in the prior 12 months, and DSM-IV depressive and anxiety disorders were assessed at both waves. Logistic regression was used to produce adjusted odds ratios (aOR) testing the associations of changes between Wave 1 and Wave 2 WHO risk levels to the presence or persistence of depression and/or anxiety disorder by each initial Wave 1 risk level. Among Wave 1 very-high-risk drinkers, lower odds of depression and/or anxiety disorders at Wave 2 were predicted by reductions in WHO risk levels of one-, two- or three-levels (aOR = 0.42, 0.37, 0.67, p-values 0.04-<.0001), as was the persistence of depression and/or anxiety disorders among those with such disorders at Wave 1 (aOR = 0.37, 0.29, 0.51, p-values .03-<.0001). Results were less consistent for participants initially drinking at lower risk levels. Among very-high-risk drinkers, reductions in the WHO drinking risk categories were associated with lower risk of depression and/or anxiety disorders. These results add to findings indicating reductions in WHO risk levels are a meaningful indicator of how individuals feel and function.
Sections du résumé
BACKGROUND
Non-abstinent drinking reductions that predict improvement in how individuals feel or function, such as the World Health Organization (WHO) drinking risk levels, may be useful outcomes in clinical trials for alcohol use disorders (AUD).
METHODS
Current drinkers in a U.S. national survey (n = 22,005) were interviewed in 2001-02 (Wave 1) and re-interviewed 3 years later (Wave 2). WHO drinking risk levels, a 4- level categorization system (very-high-risk, high-risk, moderate-risk, and low-risk drinkers) defined using estimated mean ethanol consumption (grams) per day in the prior 12 months, and DSM-IV depressive and anxiety disorders were assessed at both waves. Logistic regression was used to produce adjusted odds ratios (aOR) testing the associations of changes between Wave 1 and Wave 2 WHO risk levels to the presence or persistence of depression and/or anxiety disorder by each initial Wave 1 risk level.
RESULTS
Among Wave 1 very-high-risk drinkers, lower odds of depression and/or anxiety disorders at Wave 2 were predicted by reductions in WHO risk levels of one-, two- or three-levels (aOR = 0.42, 0.37, 0.67, p-values 0.04-<.0001), as was the persistence of depression and/or anxiety disorders among those with such disorders at Wave 1 (aOR = 0.37, 0.29, 0.51, p-values .03-<.0001). Results were less consistent for participants initially drinking at lower risk levels.
CONCLUSIONS
Among very-high-risk drinkers, reductions in the WHO drinking risk categories were associated with lower risk of depression and/or anxiety disorders. These results add to findings indicating reductions in WHO risk levels are a meaningful indicator of how individuals feel and function.
Identifiants
pubmed: 30852375
pii: S0376-8716(18)30481-2
doi: 10.1016/j.drugalcdep.2019.01.009
pmc: PMC6440807
mid: NIHMS1009362
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-235Subventions
Organisme : NIAAA NIH HHS
ID : P50 AA010761
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025309
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
J Stud Alcohol Drugs. 2008 Nov;69(6):866-77
pubmed: 18925345
Addiction. 2017 Dec;112(12):2112-2121
pubmed: 28511286
Arch Gen Psychiatry. 2007 May;64(5):566-76
pubmed: 17485608
Mol Psychiatry. 2009 Nov;14(11):1051-66
pubmed: 18427559
Alcohol Clin Exp Res. 2017 Jan;41(1):179-186
pubmed: 28019652
J Psychopharmacol. 2015 Nov;29(11):1152-8
pubmed: 26349557
Alcohol Clin Exp Res. 2017 May;41(5):1054-1062
pubmed: 28295414
Subst Abuse. 2015 Oct 27;9(Suppl 2):23-31
pubmed: 26549971
World Psychiatry. 2017 Oct;16(3):325-326
pubmed: 28941117
Neuropsychopharmacology. 2012 Jan;37(2):402-11
pubmed: 21900883
JAMA Psychiatry. 2015 Aug;72(8):757-66
pubmed: 26039070
J Stud Alcohol Drugs. 2014 May;75(3):438-46
pubmed: 24766756
Lancet Psychiatry. 2017 Jun;4(6):430-431
pubmed: 28456502
Drug Alcohol Depend. 2007 Jan 12;86(2-3):214-21
pubmed: 16919401
Drug Alcohol Depend. 2008 Jan 1;92(1-3):27-36
pubmed: 17706375
Addiction. 2017 Jun;112(6):968-1001
pubmed: 28220587
Arch Gen Psychiatry. 2004 Aug;61(8):807-16
pubmed: 15289279
Lancet Psychiatry. 2017 Jun;4(6):469-476
pubmed: 28456501
J Clin Psychiatry. 2013 Dec;74(12):e1181-9
pubmed: 24434106
Eur Addict Res. 2017;23(5):219-230
pubmed: 28934736
Alcohol Clin Exp Res. 2015 Sep;39(9):1557-70
pubmed: 26250333
Dig Dis Sci. 2017 May;62(5):1373-1380
pubmed: 28194666
BMC Health Serv Res. 2014 Feb 05;14:53
pubmed: 24499391
Drug Alcohol Depend. 2003 Jul 20;71(1):7-16
pubmed: 12821201
JAMA. 2006 May 3;295(17):2003-17
pubmed: 16670409
Addiction. 2016 Nov;111(11):1975-1984
pubmed: 27349855
Lancet. 2005 Feb 5-11;365(9458):519-30
pubmed: 15705462
Addict Sci Clin Pract. 2012 Dec 11;7:26
pubmed: 23227807
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Alcohol Alcohol. 2013 Jul-Aug;48(4):509-13
pubmed: 23531718
J Aging Health. 2015 Dec;27(8):1358-74
pubmed: 25903980
Alcohol Clin Exp Res. 2018 Nov;42(11):2256-2265
pubmed: 30204248
Arch Gen Psychiatry. 2005 Oct;62(10):1097-106
pubmed: 16203955
Alcohol Res Health. 2003;27(1):39-51
pubmed: 15301399
Soc Psychiatry Psychiatr Epidemiol. 2013 May;48(5):701-10
pubmed: 23052426
JAMA Psychiatry. 2017 Sep 1;74(9):911-923
pubmed: 28793133
J Subst Abuse Treat. 2004 Apr;26(3):237-42
pubmed: 15063919
J Stud Alcohol. 1997 Jul;58(4):365-71
pubmed: 9203117
Drug Alcohol Depend. 2018 Jun 1;187:319-326
pubmed: 29705545
Arch Gen Psychiatry. 2004 Apr;61(4):361-8
pubmed: 15066894
Soc Psychiatry Psychiatr Epidemiol. 2015 Feb;50(2):171-82
pubmed: 25563838
J Abnorm Psychol. 2012 Feb;121(1):282-8
pubmed: 21842958
Subst Abuse Treat Prev Policy. 2015 Aug 12;10:32
pubmed: 26264215
Addiction. 2016 Dec;111(12):2145-2154
pubmed: 27367263
Soc Psychiatry Psychiatr Epidemiol. 2015 Nov;50(11):1609-40
pubmed: 26210739
J Consult Clin Psychol. 2009 Aug;77(4):633-44
pubmed: 19634957
Arch Gen Psychiatry. 2007 Jul;64(7):830-42
pubmed: 17606817